絞り込み

17703

広告

Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.

著者 Rossi S , Finocchiaro G , Noia VD , Bonomi M , Cerchiaro E , Rose F , Franceschini D , Navarria P , Ceresoli GL , Beretta GD , D'Argento E , Scorsetti M , Santoro A , Toschi L
Future Oncol.2019 Nov 11 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (50view , 0users)

Full Text Sources

Medical

Miscellaneous

Research Materials

The association of tyrosine kinase inhibitors (TKIs) and local radiotherapy in -mutated non-small-cell lung cancer patients experiencing disease progression under TKIs could be a valid an option. We included 131 patients experiencing disease progression during first-line TKI. In group A, patients received TKI beyond progression and site(s) of progression were irradiated; in group B, patients remained on TKI alone beyond progression; and group C stopped TKI at first disease progression. Median overall survival resulted longer in group A versus B and C (p < 0.0001). Group A had a trend toward a longer second progression-free survival (measured from the time of first progression until second progression) versus group B (p = 0.06). TKI beyond progression in association with local ablative treatment is a valid treatment option in oligoprogressive patients.
PMID: 31709807 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード